Literature DB >> 19019946

SOCS-1 mimetics protect mice against lethal poxvirus infection: identification of a novel endogenous antiviral system.

Chulbul M Ahmed1, Rea Dabelic, Lilian W Waiboci, Lindsey D Jager, Linda L Heron, Howard M Johnson.   

Abstract

The suppressor of cytokine signaling 1 (SOCS-1) protein modulates cytokine signaling by binding to and inhibiting the function of Janus kinases (JAKs), ErbB, and other tyrosine kinases. We have developed a small tyrosine kinase inhibitor peptide (Tkip) that binds to the autophosphorylation site of tyrosine kinases and inhibits activation of STAT transcription factors. We have also shown that a peptide corresponding to the kinase-inhibitory region of SOCS-1, SOCS1-KIR, similarly interacts with the activation loop of JAK2 and blocks STAT activation. Poxviruses activate cellular tyrosine kinases, such as ErbB-1 and JAK2, in the infection of cells. We used the pathogenesis of vaccinia virus in C57BL/6 mice to determine the ability of the SOCS-1 mimetics to protect mice against lethal vaccinia virus infection. Injection of mice intraperitoneally with Tkip or SOCS1-KIR containing a palmitate for cell penetration, before and at the time of intranasal challenge with 2 x 10(6) PFU of vaccinia virus, resulted in complete protection at 100 microg. Initiation of treatment 1 day postinfection resulted in 80% survival. Administration of SOCS-1 mimetics by the oral route also protected mice against lethal effects of the virus. Both SOCS1-KIR and Tkip inhibited vaccinia virus transcription and replication at early and possibly later stages of infection. Vaccinia virus-induced phosphorylation of ErbB-1 and JAK2 was inhibited by the mimetics. Protected mice mounted a strong humoral and cellular response to vaccinia virus. The use of SOCS-1 mimetics in the treatment of poxvirus infections reveals an endogenous regulatory system that previously was not known to have an antiviral function.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19019946      PMCID: PMC2620917          DOI: 10.1128/JVI.01138-08

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  36 in total

Review 1.  Immunology 101 at poxvirus U: immune evasion genes.

Authors:  B Moss; J L Shisler
Journal:  Semin Immunol       Date:  2001-02       Impact factor: 11.130

Review 2.  The role of suppressors of cytokine signaling (SOCS) proteins in regulation of the immune response.

Authors:  Warren S Alexander; Douglas J Hilton
Journal:  Annu Rev Immunol       Date:  2004       Impact factor: 28.527

3.  Biochemical and functional analysis of smallpox growth factor (SPGF) and anti-SPGF monoclonal antibodies.

Authors:  Mikyung Kim; Hailin Yang; Sung-Kwon Kim; Pedro A Reche; Rebecca S Tirabassi; Rebecca E Hussey; Yasmin Chishti; James G Rheinwald; Tiara J Morehead; Tobias Zech; Inger K Damon; Raymond M Welsh; Ellis L Reinherz
Journal:  J Biol Chem       Date:  2004-04-07       Impact factor: 5.157

4.  Deletion of the vaccinia virus growth factor gene reduces virus virulence.

Authors:  R M Buller; S Chakrabarti; J A Cooper; D R Twardzik; B Moss
Journal:  J Virol       Date:  1988-03       Impact factor: 5.103

5.  Poxvirus infection rapidly activates tyrosine kinase signal transduction.

Authors:  J Masters; A A Hinek; S Uddin; L C Platanias; W Zeng; G McFadden; E N Fish
Journal:  J Biol Chem       Date:  2001-10-08       Impact factor: 5.157

6.  A simple method for displaying the hydropathic character of a protein.

Authors:  J Kyte; R F Doolittle
Journal:  J Mol Biol       Date:  1982-05-05       Impact factor: 5.469

Review 7.  Monitoring of human immunological responses to vaccinia virus.

Authors:  Richard Harrop; Matthew G Ryan; Hana Golding; Irina Redchenko; Miles W Carroll
Journal:  Methods Mol Biol       Date:  2004

Review 8.  SOCS regulation of the JAK/STAT signalling pathway.

Authors:  Ben A Croker; Hiu Kiu; Sandra E Nicholson
Journal:  Semin Cell Dev Biol       Date:  2008-07-30       Impact factor: 7.727

9.  Characterization of a peptide inhibitor of Janus kinase 2 that mimics suppressor of cytokine signaling 1 function.

Authors:  Lawrence O Flowers; Howard M Johnson; Mustafa G Mujtaba; Morgan R Ellis; S Mohammed I Haider; Prem S Subramaniam
Journal:  J Immunol       Date:  2004-06-15       Impact factor: 5.422

10.  Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections.

Authors:  Robert O Baker; Mike Bray; John W Huggins
Journal:  Antiviral Res       Date:  2003-01       Impact factor: 10.103

View more
  14 in total

1.  SOCS1/3 expression levels in HSV-1-infected, cytokine-polarized and -unpolarized macrophages.

Authors:  Adam Craig Reichard; Nagarjuna Reddy Cheemarla; Nancy Jane Bigley
Journal:  J Interferon Cytokine Res       Date:  2014-06-23       Impact factor: 2.607

2.  Orthopoxvirus inhibitors that are active in animal models: an update from 2008 to 2012.

Authors:  Donald F Smee
Journal:  Future Virol       Date:  2013-09       Impact factor: 1.831

Review 3.  The use of structural biology in Janus kinase targeted drug discovery.

Authors:  Nilda L Alicea-Velázquez; Titus J Boggon
Journal:  Curr Drug Targets       Date:  2011-04       Impact factor: 3.465

4.  Suppressors of cytokine signaling abrogate diabetic nephropathy.

Authors:  Guadalupe Ortiz-Muñoz; Virginia Lopez-Parra; Oscar Lopez-Franco; Paula Fernandez-Vizarra; Beñat Mallavia; Claudio Flores; Ana Sanz; Julia Blanco; Sergio Mezzano; Alberto Ortiz; Jesus Egido; Carmen Gomez-Guerrero
Journal:  J Am Soc Nephrol       Date:  2010-02-25       Impact factor: 10.121

5.  Silencing suppressor of cytokine signaling-1 (SOCS1) in macrophages improves Mycobacterium tuberculosis control in an interferon-gamma (IFN-gamma)-dependent manner.

Authors:  Berit Carow; Xiang qun Ye; Dolores Gavier-Widén; Sabin Bhuju; Wulf Oehlmann; Mahavir Singh; Markus Sköld; Lech Ignatowicz; Akihiko Yoshimura; Hans Wigzell; Martin E Rottenberg
Journal:  J Biol Chem       Date:  2011-05-27       Impact factor: 5.157

6.  The kinase inhibitory region of SOCS-1 is sufficient to inhibit T-helper 17 and other immune functions in experimental allergic encephalomyelitis.

Authors:  Lindsey D Jager; Rea Dabelic; Lilian W Waiboci; Kenneth Lau; Mohammad S Haider; Chulbul M I Ahmed; Joseph Larkin; Samuel David; Howard M Johnson
Journal:  J Neuroimmunol       Date:  2010-12-04       Impact factor: 3.478

7.  Phosphorylation events during viral infections provide potential therapeutic targets.

Authors:  Julie A Keating; Rob Striker
Journal:  Rev Med Virol       Date:  2011-11-24       Impact factor: 6.989

8.  Suppression of interferon lambda signaling by SOCS-1 results in their excessive production during influenza virus infection.

Authors:  Haitao Wei; Song Wang; Qinghuang Chen; Yuhai Chen; Xiaojuan Chi; Lianfeng Zhang; Shile Huang; George F Gao; Ji-Long Chen
Journal:  PLoS Pathog       Date:  2014-01-02       Impact factor: 6.823

Review 9.  The Potential Therapeutic Application of Peptides and Peptidomimetics in Cardiovascular Disease.

Authors:  Carlota Recio; Francesco Maione; Asif J Iqbal; Nicola Mascolo; Vincenzo De Feo
Journal:  Front Pharmacol       Date:  2017-01-06       Impact factor: 5.810

Review 10.  Perspective of Use of Antiviral Peptides against Influenza Virus.

Authors:  Sylvie Skalickova; Zbynek Heger; Ludmila Krejcova; Vladimir Pekarik; Karel Bastl; Jozef Janda; Frantisek Kostolansky; Eva Vareckova; Ondrej Zitka; Vojtech Adam; Rene Kizek
Journal:  Viruses       Date:  2015-10-20       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.